Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left
Apellis Pharmaceuticals is off the Nasdaq tape now that Biogen has finished its buyout. The focus moves to Biogen and if it can pull enough revenue from Syfovre and Empaveli to make the acquisition pay.
